Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 115 Squamous Cell Carcinoma of Head and Neck 61 Triple Negative Breast Neoplasms 57 Melanoma 54 Neoplasm Metastasis 49 Lung Neoplasms 49 Breast Neoplasms 41 Neoplasms 36 Colorectal Neoplasms 35 Head and Neck Neoplasms 25 Endometrial Neoplasms 25 Carcinoma, Renal Cell 24 Uterine Cervical Neoplasms 21 Stomach Neoplasms 21 Ovarian Neoplasms 21 Carcinoma, Transitional Cell 21 Urinary Bladder Neoplasms 20 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Esophageal Neoplasms 16 Recurrence 15 Carcinoma, Hepatocellular 14 Pancreatic Neoplasms 13 Sarcoma 12 Carcinoma, Squamous Cell 12 Glioblastoma 11 Esophageal Squamous Cell Carcinoma 11 Carcinoma 11 Prostatic Neoplasms 10 Brain Neoplasms 10 Carcinoma, Merkel Cell 9

Interventions

pembrolizumab 1 Zoledronic Acid 1 Pemetrexed 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Chordoma × pembrolizumab × Clear all

NCT06794645 2025-01-27

Pembrolizumab and Pemetrexed for Progressive Chordoma

Saint John's Cancer Institute

Phase 2 Recruiting

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡